CD BioSciences, a biotechnology company serving the New York City metro area, announced the launch of a comprehensive one-stop anti-aging drug development service package. This initiative targets pharmaceutical companies, research institutions, and academic investigators engaged in developing cutting-edge anti-aging therapies. By combining advanced technical platforms with industry expertise, CD BioSciences aims to support partners throughout the entire drug development cycle, from early discovery to preclinical stages.
The significance of this announcement lies in its potential to accelerate anti-aging drug development, a field that faces lengthy timelines and high entry barriers. The New York metro area, a hub for biotech innovation, stands to benefit as local researchers gain access to integrated services that streamline the R&D process. The company's diversified anti-aging drug discovery services cover key molecules and signaling pathways such as AMPK, mTOR, SIRT1, NF-κB, p53, and PI3K, which are closely associated with aging mechanisms. Additionally, it encompasses mainstream anti-aging drug categories including senolytics, senomorphics, calorie restriction mimetics, autophagy inducers, anti-inflammatory drugs, antioxidants, telomerase activators, and mitochondrial modulators.
CD BioSciences' services extend to a complete preclinical development system, covering multiple key links to ensure scientificity and reliability. Its anti-aging pharmacology services include both in vitro and in vivo evaluations to verify therapeutic efficacy. The in vitro ADME services and in vivo pharmacokinetic services enable early assessment of pharmacokinetic behaviors, while toxicity testing and safety pharmacology services evaluate potential toxic effects on key physiological systems. As a specialized aging disease model CRO, CD BioSciences has built a comprehensive and customizable preclinical aging model platform, offering organ-specific aging models, general aging models, longevity models, and aging-related disease models. These models assist in uncovering aging mechanisms, validating therapeutic targets, and evaluating drug efficacy and safety.
This launch addresses critical challenges in anti-aging R&D, particularly for New York metro area institutions that require efficient, integrated solutions. By providing a one-stop service, CD BioSciences reduces the time and complexity involved in drug development, potentially accelerating the delivery of new therapies to market. The company's commitment to optimizing technical platforms and service systems positions it as a key partner for worldwide institutions in anti-aging drug development. More information about their services can be found at https://www.cd-biosciences.com.
